trial

Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)

NCTId NCT02181803
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 55 (actual)
Sponsored by Merck Sharp & Dohme LLC
Primary completion 2015-04-23
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
55 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2014-08-05
Primary completion
2015-04-23
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
ElpipodectBase Monotherapy

Sponsors

Merck Sharp & Dohme LLCLead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
55
Phase
PHASE1
Primary Completion Date
2015-04-23
Status
COMPLETED
relationships
The graph out of here
drug
Elpipodect
drug
Base Monotherapy
drug
lead_sponsor
Merck Sharp & Dohme LLC
company
indication
Schizophrenia
indication
Schizophrenia
indication